Loading
A phase 1/2 trial of Afamitresgene autoleucel in osteosarcoma, run by USWM CT, LLC, now recruiting.
SPEARHEAD-3 Pediatric Study is a phase 1/2 interventional study registered as NCT05642455 by USWM CT, LLC, with 20 participants planned, started 2023-09-01 and due to reach its primary completion in 2026-10-01. Interventions recorded: Afamitresgene autoleucel. Conditions listed: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/